Real-world outcomes of autologous and allogeneic hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in the era of novel therapies: a Canadian perspective.

[1]  M. Kersten,et al.  Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study , 2020, Haematologica.

[2]  R. Bouabdallah,et al.  Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. , 2020, Blood advances.

[3]  I. Moiseev,et al.  Safety and efficacy of allogeneic stem cell transplantation after nivolumab therapy for patients with relapsed/refractory classical Hodgkin lymphoma , 2019 .

[4]  M. Shipp,et al.  Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087. , 2019, Blood.

[5]  M. Perales,et al.  Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  S. Yantorno,et al.  Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment , 2019, Bone Marrow Transplantation.

[7]  C. Martínez,et al.  Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). , 2019 .

[8]  P. Zinzani,et al.  PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series , 2019, Haematologica.

[9]  P. Mazza,et al.  Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients , 2019, Annals of Hematology.

[10]  W. Faridi,et al.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  M. Gobbi,et al.  Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  A. Herrera.  Where does PD-1 blockade fit in HL therapy? , 2018, Hematology. American Society of Hematology. Education Program.

[13]  R. Dada,et al.  Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety , 2018, European journal of haematology.

[14]  K. Blum.  Treatment-Resistant Hodgkin Lymphoma: Defining the Role of Autologous Transplantation , 2018, Cancer journal.

[15]  R. Advani,et al.  Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. , 2018, Blood.

[16]  S. Montoto,et al.  Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party , 2018, British journal of haematology.

[17]  K. Savage,et al.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Advani,et al.  Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. , 2018, Blood.

[19]  G. Oliveira,et al.  NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. , 2018, Blood.

[20]  J. Connors,et al.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma , 2017, The New England journal of medicine.

[21]  S. Akhtar.  High dose chemotherapy and autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: Emerging questions, newer agents, and changing paradigm. , 2017, Hematology/oncology and stem cell therapy.

[22]  S. Schuster,et al.  Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis , 2017, American journal of hematology.

[23]  O. Casasnovas,et al.  Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  C. Moskowitz.  Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma. , 2016, Hematology. American Society of Hematology. Education Program.

[25]  O. Press,et al.  Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial , 2016 .

[26]  R. Gascoyne,et al.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Santoro,et al.  Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Scott E. Smith,et al.  Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. , 2016, Blood.

[29]  F. d'Amore,et al.  Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. , 2016, The New England journal of medicine.

[30]  A. Nademanee,et al.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[31]  A. Santoro,et al.  Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. , 2015, Blood.

[32]  N. Skoetz,et al.  High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis. , 2014, Critical reviews in oncology/hematology.

[33]  G. Freeman,et al.  Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. , 2013, Blood.

[34]  R. Advani,et al.  Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Zelenetz,et al.  Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. , 2012, Blood.

[37]  A. Zelenetz,et al.  Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. , 2010, Blood.

[38]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[39]  A. Zelenetz,et al.  Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma , 2009, British journal of haematology.

[40]  A. Horwich,et al.  Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  K. Bradstock,et al.  Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  A. Zelenetz,et al.  Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‐proven primary refractory Hodgkin's disease , 2004, British journal of haematology.

[43]  K. Ding,et al.  Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  A. Zelenetz,et al.  Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma , 2003, Bone Marrow Transplantation.

[45]  J. Connors,et al.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Dirk Hasenclever,et al.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.

[47]  T. Lister,et al.  Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[49]  D. Weisenburger,et al.  Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. , 1992, Blood.